HC Wainwright Reaffirms “Buy” Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

HC Wainwright reiterated their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report released on Friday morning,Benzinga reports. They currently have a $3.00 price objective on the stock.

Barinthus Biotherapeutics Stock Down 2.0 %

Shares of NASDAQ BRNS opened at $0.99 on Friday. Barinthus Biotherapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $4.16. The firm’s 50-day simple moving average is $1.01 and its 200 day simple moving average is $1.12. The stock has a market cap of $39.83 million, a P/E ratio of -0.66 and a beta of -0.80.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $14.97 million for the quarter. On average, sell-side analysts anticipate that Barinthus Biotherapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. bought a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics accounts for approximately 0.0% of Gilead Sciences Inc.’s portfolio, making the stock its 14th largest holding. Gilead Sciences Inc. owned approximately 1.54% of Barinthus Biotherapeutics at the end of the most recent quarter. 25.20% of the stock is owned by institutional investors and hedge funds.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.